Current standard of care treatment for IBD not only includes immunosuppressive medication and biologic therapies such as anti-TNF therapies (infliximab), α4β7 blockade (Vedolizumab) is now routinely used for IBD patients to prevent mucosal T cell homing (68). This evidence concerns the gene TNF and inflammatory bowel disease.